ZOLL TherOx has secured $16.8 million in funding from investors, marking a significant capital infusion for the company focused on advancing heart attack treatment. Based in San Jose, California, ZOLL TherOx is dedicated to improving outcomes for patients experiencing acute myocardial infarction (AMI) through its innovative SuperSaturated Oxygen (SSO2) Therapy. This investment will support the company's ongoing efforts to commercialize its therapy for the sizeable AMI patient population.
The core of ZOLL TherOx's offering is SSO2 Therapy, a treatment designed to save heart muscle and improve patient lives by reducing infarct size after a heart attack. This therapy leverages the known benefits of hyperbaric oxygen treatment, infusing superoxygenated blood to enhance microvascular flow immediately following a successful percutaneous coronary intervention (PCI). Delivered as a one-time, 60-minute infusion through a small catheter, the superoxygenated blood helps reduce capillary swelling, restore blood flow to surrounding tissue, and ultimately decrease the area of damaged heart muscle. SSO2 Therapy is indicated for use after PCI with stenting within six hours of anterior AMI symptoms caused by a left anterior descending artery infarct lesion.
This funding round is poised to accelerate ZOLL TherOx's commercialization strategy and expand the reach of SSO2 Therapy. The capital will be strategically deployed to scale operations, enhance market penetration, and support further clinical and development initiatives. The investment reflects confidence in the therapy's potential to address a critical unmet need in cardiovascular care and improve patient prognosis following severe heart attacks.
With this new financial backing, ZOLL TherOx is well-positioned to continue its mission of transforming AMI treatment. The company plans to broaden access to SSO2 Therapy, aiming to save more hearts and improve the quality of life for a greater number of patients worldwide. This funding represents a pivotal step in the company's growth trajectory and its commitment to advancing medical innovation in cardiology.
